Literature DB >> 10844918

Reported management of lung cancer in Victoria in 1993: comparison with best practice. Anti-Cancer Council of Victoria Lung Cancer Study Group.

G E Richardson1, V J Thursfield, G G Giles.   

Abstract

OBJECTIVE: To determine recent patterns of management of lung cancer in Victoria in order to stimulate interest in the development of Australian consensus guidelines.
DESIGN: A cross-sectional survey of doctors responsible for the care of an incident series of lung cancer patients in 1996-1997. PARTICIPANTS: 1054 people diagnosed with primary lung cancer in the State of Victoria between 1 January 1993 and 31 July 1993 and notified to the Victorian Cancer Registry. MAIN OUTCOME MEASURES: Method of diagnosis; tumour characteristics; factors affecting management plan; first-line and subsequent treatment; outcome; and patients' current status.
RESULTS: Questionnaires were completed for 868 eligible patients (82%): 635 (73%) diagnosed with non-small-cell lung cancer, 124 (14%) diagnosed with small-cell lung cancer, and 109 (13%) with no histological diagnosis. Chest x-ray (814 patients; 94%) and computed tomography (CT) of the chest and abdomen (589 patients; 68%) were the most common investigations, and was the only diagnostic procedure in 48 patients (6%). Treatments were radiotherapy alone or in combination (385 patients; 44%), surgery alone or in combination (196 patients; 23%), chemotherapy alone or in combination (152 patients; 18%); 215 patients (25%) received no antitumour therapy. 243 patients (28%) were treated initially with curative intent. A further 399 (46%) were treated initially with palliative intent, and in 219 (55%) of these good symptom control was achieved. For 427 patients (49%) tumour size was not recorded. While 23% of non-small-cell patients had limited disease, only 8% were investigated with mediastinoscopy. Only four patients (13%) with limited-stage, small-cell lung cancer had combined-modality treatment. There was little use of adjuvant chemotherapy or neoadjuvant therapy. The five-year crude survival rate was 11%.
CONCLUSIONS: The demographics of lung cancer in Victoria are similar to other population-based studies. Patterns of management are not uniform, and are inconsistent with current published guidelines.

Entities:  

Mesh:

Year:  2000        PMID: 10844918

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  8 in total

1.  A population-based study of gefitinib in patients with non-small cell lung cancer.

Authors:  Kenji Hayashibara; Hiroaki Satoh; Yoko Shinohara; Masaharu Inagaki; Takayuki Kaburagi; Toshio Hashimoto; Koichi Kurishima; Hiroichi Ishikawa; Hideo Ichimura; Takeshi Nawa; Yasunori Funayama; Takeshi Matsumura; Katsunori Kagohashi; Takeshi Endo; Kinya Furukawa; Koji Kishi; Masaaki Sumi; Koichi Kamiyama; Shigemi Ishikawa
Journal:  Med Oncol       Date:  2008-10-31       Impact factor: 3.064

Review 2.  Decisions for lung cancer chemotherapy: the influence of physician and patient factors.

Authors:  Patricia M Davidson; Moyez Jiwa; Alice J Goldsmith; Sarah J McGrath; Michelle Digiacomo; Jane L Phillips; Meera Agar; Phillip J Newton; David C Currow
Journal:  Support Care Cancer       Date:  2011-05-27       Impact factor: 3.603

3.  Do multidisciplinary meetings follow guideline-based care?

Authors:  Shalini K Vinod; Mark A Sidhom; Geoff P Delaney
Journal:  J Oncol Pract       Date:  2010-11       Impact factor: 3.840

4.  Lung cancer patterns of care in south western Sydney, Australia.

Authors:  S K Vinod; G P Delaney; A E Bauman; M B Barton
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

5.  Bevacizumab-containing chemotherapy for non-small cell lung cancer patients: a population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.

Authors:  Hiroyuki Nakamura; Hiroaki Satoh; Takayuki Kaburagi; Yoshihiro Nishimura; Yoko Shinohara; Masaharu Inagaki; Takeo Endo; Takefumi Saito; Kenji Hayashihara; Nobuyuki Hizawa; Koichi Kurishima; Takeshi Nawa; Katsunori Kagohashi; Koji Kishi; Hiroichi Ishikawa; Hideo Ichimura; Toshio Hashimoto; Yukio Sato; Mitsuaki Sakai; Koichi Kamiyama; Takeshi Matsumura; Koji Unoura; Kinya Furukawa
Journal:  Med Oncol       Date:  2012-11-02       Impact factor: 3.064

6.  S-1-containing chemotherapy for patients with non-small-cell lung cancer: A population-based observational study by the Ibaraki thoracic integrative (POSITIVE) research group.

Authors:  Masaharu Inagaki; Yoko Shinohara; Takayuki Kaburagi; Takeo Endo; Shinsuke Homma; Nobuyuki Hizawa; Koji Kishi; Hiroyuki Nakamura; Kenji Hayashihara; Takefumi Saito; Koichi Kurishima; Hiroichi Ishikawa; Hideo Ichimura; Takeshi Nawa; Norihiro Kikuchi; Kunihiko Miyazaki; Takahide Kodama; Hiroaki Satoh; Kinya Furukawa
Journal:  Mol Clin Oncol       Date:  2016-03-21

7.  Factors Associated With the Use of Radiation Therapy in Patients With Stage III Non-small Cell Lung Cancer in Alberta, Canada: A Population-based Study.

Authors:  Hong-Wei Liu; Marc Kerba; Gerald Lim; Zsolt Gabos; Ivo A Olivotto; Anil Abraham Joy; Wilson Roa; Zoann Nugent; Harold Lau
Journal:  Cureus       Date:  2016-10-27

8.  Lung cancer referral patterns in the former Yorkshire region of the UK.

Authors:  P P Melling; A C Hatfield; M F Muers; M D Peake; C J Storer; C E Round; R A Haward; S M Crawford
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.